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Genetically Directed Production of Recombinant, Isosteric
and Nonhydrolysable Ubiquitin Conjugates
Mathew Stanley and Satpal Virdee*[a]
Introduction
Post-translational modification of proteins with ubiquitin (Ub)
regulates various cellular processes, and defects within this
pathway result in numerous pathologies.[1] Ubiquitylation is
orchestrated by a series of enzymes (E1s, E2s and E3s) whose
action culminates in the covalent attachment of the Ub car-
boxy terminus to Ne-amino groups of lysine residues by an iso-
peptide bond.[2] Ub itself has seven lysines (Lys6, Lys11, Lys27,
Lys29, Lys33, Lys48 and Lys63) that can accept another Ub
molecule. This results in the formation of seven different iso-
peptide-linked polyUb chains, which have been proposed to
serve as a cellular code.[3] Despite the presence of all linkage
types in cells, the cellular roles of the various linkages are
poorly defined. Furthermore, Ub conjugation is reversible, as
the isopeptide bond can be hydrolysed by deubiquitylating
enzymes (DUBs), around 100 of which are encoded in the
human genome.[4]
Studying the cellular roles of distinct Ub linkages poses
a number of challenges because of complications in the prepa-
ration of homogenously modified protein and an inability to
genetically disrupt distinct linkage types in cells. Nonhydrolysa-
ble analogues of polyUb chains of defined linkage type could
serve as powerful probes by inhibiting linkage-specific process-
es. Assessment of their effects on biological function could
help establish their roles.[5] DUBs are also key cellular regulators
and are attractive therapeutic targets. However, the over-
whelming number of proteins that associate with DUBs raises
the question: which ones are bona fide substrates?[6] Nonhy-
drolysable analogues of ubiquitylated substrates could be
used as affinity probes to address this question, as DUBs
would be predicted to confer specificity for the modified form
of the substrate, and the nonhydrolysable nature would cir-
cumvent complications associated with DUB-mediated cleav-
age of the native counterpart. Nonhydrolysable Ub conjugates
of recombinant protein would also facilitate structure determi-
nation of substrate–DUB complexes, the raising substrate-spe-
cific antibodies (where native conjugates would be hydrolysed
in vivo) and target validation of DUB inhibitors.
Current methods for the nonhydrolysable conjugation of Ub
to recombinant protein use a linkage that typically has com-
promised isostery with the native isopeptide bond (Figure S1
in the Supporting Information).[5, 7] This is often exacerbated by
the steric and electrostatic properties of the amino acid scaf-
folds bearing the requisite reactive handles. Despite a recent
refinement[8] of the cysteine chemistry first reported by Wilkin-
son and co-workers,[7a] this approach still precludes the use of
recombinant substrates containing more than one cysteine.
Solid-phase peptide synthesis (SPSS) approaches for preparing
nonhydrolysable Ub conjugates have also been described, but
these require specialist expertise and are not generally applica-
ble.[9] Although conjugates formed with triazole-based linkages
have been employed for biological studies,[5, 7d,10] the behaviour
towards receptors or DUBs that recognise the linkage itself[11]
or that specifically “sense” the inter-ubiquitin distance in a par-
ticular linkage[12] is unknown. Furthermore, there is no experi-
mental structure of a nonhydrolysable conjugate, and a com-
parison of the affinity towards DUBs and Ub receptors relative
to their native counterparts has not been investigated.
Here we report a method for genetically incorporating an
aminooxy functionality into recombinant proteins by the incor-
We describe the genetically directed incorporation of amino-
oxy functionality into recombinant proteins by using a mutant
Methanosarcina barkeri pyrrolysyl-tRNA synthetase/tRNACUA
pair. This allows the general production of nonhydrolysable
ubiquitin conjugates of recombinant origin by bioorthogonal
oxime ligation. This was exemplified by the preparation of
nonhydrolysable versions of diubiquitin, polymeric ubiquitin
chains and ubiquitylated SUMO. The conjugates exhibited un-
rivalled isostery with the native isopeptide bond, as inferred
from structural and biophysical characterisation. Furthermore,
the conjugates functioned as nanomolar inhibitors of deubi-
quitylating enzymes and were recognised by linkage-specific
antibodies. This technology should provide a versatile platform
for the development of powerful tools for studying deubiquity-
lating enzymes and for elucidating the cellular roles of diverse
polyubiquitin linkages.
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poration of the unnatural amino acid aminooxy-l-lysine (1,
Scheme 1A) by using an evolved Methanosarcina barkeri (Mb)
pyrrolysyl-tRNA synthetase (PylS)/tRNACUA pair. This enables the
site-specific, nonhydrolysable ubiquitylation of proteins by bio-
orthogonal oxime ligation.[13] We demonstrate the generality of
this approach by preparing diubiquitin (diUb) of distinct link-
age types and SUMO2 (small ubiquitin-like modifier 2) modi-
fied with Ub at a physiologically relevant site. Structural, bio-
chemical and biophysical characterisation of these conjugates
revealed that they accurately reflect the topology of their
native counterparts. They also serve as potent (nanomolar)
DUB inhibitors and provide insight into how the substrate spe-
cificity of a ubiquitin carboxy terminal hydrolase (UCH) family
DUB towards its substrates is achieved. We also describe
a hybrid strategy that involves genetic code expansion and
intein chemistry to produce extended nonhydrolysable Ub
polymers. This technology should be valuable for the identifi-
cation of proteins that confer specificity for topologically dis-
tinct Ub polymers and ubiquitylated substrates, and also for
probing the cellular roles of Ub linkages.
Results and Discussion
Genetically encoded e-aminooxy-l-lysine for the production
of nonhydrolysable ubiquitin conjugates
Simple synthetic peptides containing an aminooxy functionali-
ty in place of the e-amino functionality of a lysine residue can
undergo bioorthogonal oxime ligation with Ub carrying a C-
terminal aldehyde group.[14] This furnishes a stable nonhydro-
lysable oxime-linked mimic that has high isostery with the iso-
peptide bond. However, not only is this approach restricted to
synthetic peptides, it also introduces a potentially perturbing
unnatural amide linkage within the lysine side chain and dis-
rupts the electronic properties of the Ub C terminus (Fig-
ure S1).[14] Incorporating 1 (Scheme 1A) by genetic code expan-
sion based on the Mb PylS/tRNACUA pair
[15] would extend this
technology to recombinant protein substrates, thereby ena-
bling the production of nonhydrolysable conjugates that have
unprecedented isostery with the isopeptide bond (Scheme 1B,
Figure S1). However, we anticipated that it would be challeng-
ing to evolve a mutant Mb PylS/tRNACUA pair that could selec-
tively recognise 1 (that differs from native lysine by conserva-
tive replacement of the e-methylene group with an e-oxygen
atom) yet exclude structurally similar and cellularly abundant
lysine. Furthermore, a free aminooxy group in the cell could
potentially undergo oxime formation with cellular keto com-
pounds such as pyruvate.
We considered a latent Ne-protected form of 1 that has pre-
viously been employed for structurally similar lysine ana-
logues.[16] The Ne-protecting group would also serve as a recog-
nition element for an Mb PylS/tRNACUA pair. The protecting
group could then be removed post-translationally by chemical
methods.[17] Thus we synthesised Ne-(tert-butyloxycarbonyl)-
protected aminooxy-l-lysine (2 ; Scheme 1A). Deprotection of
the Boc group by acid treatment would furnish 1. The Boc-pro-
tected derivative was initially chosen, as Ne-(tert-butyloxycar-
bonyl)-l-lysine (4 ; Scheme 1A) is a highly efficient substrate of
the wild-type PylS/tRNACUA pair.
[18] Derivatives of 4 modified at
the neighbouring d-position can be incorporated with an
evolved SHKRS/tRNACUA pair that contains a Y349W mutation
in the PylS gene.[19] We therefore tested the abilities of both
systems to direct the incorporation of 1 mm 2 into C-terminally
His-tagged Ub with a TAG codon at position 6.[17] We found
that 2 was not incorporated by the wild-type PylS/tRNACUA pair
despite, as expected, efficient incorporation of 4 (Figure 1A).
However, the SHKRS/tRNACUA pair incorporated 2 with efficien-
cy comparable to that of the PylS/tRNACUA pair with 4 (Fig-
ure 1A). These results verify the first route to genetically direct
the incorporation of aminooxy functionality into recombinant
proteins, and demonstrate that in the context of the wild-type
PylS/tRNACUA pair, the Y349W mutation permits incorporation
of lysine derivatives augmented at the e-position as well as the
d-position.[19]
We next designed and synthesised a photocaged variant of
aminooxy-l-lysine, 3 (Scheme 1A). This would allow mild
photo-deprotection of the aminooxy group (Scheme 1B),[20] as
has been demonstrated in live cells with the analogous lysine
derivative.[21] Not only would this broaden the scope for form-
ing nonhydrolysable Ub conjugates of recombinant proteins in
vitro, but it also paves the way for photoactivated bioorthogo-
nal labelling of proteins in live cells. As an evolved PylS/
tRNACUA pair (PCKRS/tRNACUA) has been shown to direct the in-
corporation of photocaged lysine,[21] we tested the incorpora-
tion of 3 into superfolder green fluorescent protein (sfGFP)
with a TAG stop codon at position 150 and a C-terminal hexa-
histidine tag,[22] by using the PCKRS/tRNACUA pair and a PCKRS/
tRNACUA pair combined with the Y349W mutation (PCKRS*/
tRNACUA). Immunoblotting against the His6 tag revealed that in-
Scheme 1. Genetic incorporation of e-aminooxy-l-lysine via acid- and photo-
labile precursors. A) 1, aminooxy-l-lysine (aminooxylysine); 2, Ne-(tert-butyl-
oxycarbonyl)aminooxylysine; 3, Ne-photocaged aminooxylysine; 4, Ne-(tert-
butyloxycarbonyl)- l-lysine. B) Genetically directing isosteric and nonhydro-
lysable ubiquitin conjugation. Incorporation of 2 or 3 by an evolved MbPylS/
tRNACUA pair enables the incorporation of the latent aminooxy functionality.
Acidolysis or photolysis provides a facile route to the site-specific incorpora-
tion of 1. Facile oxime ligation with ubiquitin aldehyde (Ub-CHO) furnishes
a nonhydrolysable isosteric mimetic of the isopeptide bond. The geometry
of the oxime conjugate largely reflects that of the native isopeptide counter-
part.
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corporation of 3 was possible albeit inefficient, and, surprising-
ly, efficiency was higher with PCKRS (Figure S2). These results
indicate that the Y349W mutant only facilitates incorporation
of e-augmentations of lysine derivatives in certain contexts,
and alternative mutations can have similar effect, presumably
by allosteric restructuring of the active site.
Production of nonhydrolysable analogues of diUb
We expressed and purified 3.5 mg of His-tagged Ub containing
2 at position 6 (Ub-BocONH2K6; Figure 1B), and characterised
it by ESI-MS (Figure 1C). The C-terminal His-tag was removed
by treatment with the DUB UCH-L3,[17] then Ub-BocONH2K6
was purified by reversed-phase (RP)-HPLC (Figure 1D). The Boc
protecting group was subsequently removed by treatment
with 60% TFA to yield Ub-ONH2K6, and the polypeptide was
recovered by ether precipitation[17] (Figure 1E). In parallel, we
prepared Ub aldehyde (Ub-CHO) as described previously.[23] In-
cubation of Ub-ONH2K6 with a twofold excess of Ub-CHO in
denaturing buffer for 1 h at pH 6 resulted in formation of the
site-specifically conjugated diUb product (UbK62-ox); this was
purified by RP-HPLC, refolded and characterised by ESI-MS and
SDS-PAGE (Figures 2A, D and S3). Resistance to DUB hydrolysis
was confirmed by treatment with increasing concentrations of
the DUB USP21[24] (Figure 2B). We observed no hydrolysis of
UbK62-ox at 37 8C for 1 h (even with 800 nm enzyme), whereas
native K6-linked diUb exhibited near complete hydrolysis in
the presence of 800 nm USP21 after 1 h (Figure 2B). Prepara-
tion of K48-linked diUb was also carried out by expression of
Ub containing a TAG codon at position 48 (Figures 2D and S3).
Production of nonhydrolysable analogues of ubiquitylated
SUMO
In order to explore the generality of preparing nonhydrolysa-
ble Ub conjugates, we prepared a nonhydrolysable isostere of
native SUMO ubiquitylated at Lys11 (Ub-SUMO2K11). As
SUMO2 has a native cysteine, this would test the compatibility
of our strategy with cysteine-containing proteins. Arsenic-in-
duced formation of Ub-SUMO2K11 on promyelocytic leukaemia
protein (PML) leads to resolution of acute promyelocytic leu-
kaemia (APL).[25] The physiological DUB that reverses this conju-
gation is unknown. Intriguingly, DUBs belonging to the Ub C-
terminal hydrolase (UCH) family,[4] which have historically been
considered inactive towards ubiquitylated proteins, have re-
cently been shown to have high activity towards Ub-
SUMO2K11.[26] As the mechanism of this activity is unknown,
an isosteric yet nonhydrolysable analogue of Ub-SUMO2K11
would be valuable for identifying DUBs that remove Ub from
PML conjugates, as well as a structural tool for determining
the activity requirements of UCH-family DUBs. We explored the
possibility of carrying out the production of oxime-linked Ub-
SUMO2K11 (Ub-SUMO-ox) on folded protein, without chaotrop-
ic salts, by using a one-pot deprotection–ligation strategy. His-
tagged SUMO2 bearing 2 at position 11 (SUMO-BocONH2K11)
was expressed in good yield (3 mgL¢1 culture medium; Fig-
ures S4 and S5). After purification, acid deprotection of the Boc
group was carried out on the folded protein.[27] Quantitative re-
moval of the Boc group was confirmed by LC-MS (Figure S6).
The pH was then raised to pH 7, and a twofold excess of Ub-
CHO was added. Aniline-catalysed oxime ligation[28] at 37 8C
was then monitored by LC-MS. The reaction went to near com-
pletion after 15 h (Figure 2C), and the oxime-linked conjugate
(Ub-SUMO-ox) was purified under native conditions by size-
exclusion chromatography and characterised by SDS-PAGE and
ESI-MS (Figures 2D, E and S3).
Structural characterisation of oxime-linked diUb
In order to unequivocally demonstrate that the oxime conju-
gates accurately mirrored the structure of native isopeptide-
linked conjugates we solved a crystal structure of UbK62-ox.
The crystal structure of native K6-linked diUb (UbK62) has been
determined, and this served as a reference to assess the isoste-
ry of the oxime-linked counterpart.[17] UbK62-ox readily formed
cubic crystals under identical conditions to those employed for
UbK62, thus enabling determination of a 3.5 æ crystal structure
(Figure 3A and Table S1). The topology of UbK62-ox accurately
mirrored that of native UbK62 (backbone RMSD 1.1 æ). An im-
portant consideration with our strategy is that the oxime link-
age could potentially form a mixture of cis and trans re-
gioisomers, thereby giving rise to structural heterogeneity.[29]
However, unambiguous electron density for the carboxy termi-
nal residues of the distal Ub molecule and the oxime linkage
with incorporated 1 was consistent with the trans regioisomer
Figure 1. Characterisation of the genetically directed incorporation of 2 at
position 6 of ubiquitin. A) E. coli cells contained a C-terminally His-tagged Ub
gene with a TAG codon at position 6, with either the wild-type MbPylS/
tRNACUA pair or the SHKRS/tRNACUA pair that contains a Y349W mutation.
Cells containing wild-type MbPylS/tRNACUA pair produce full-length protein
in the presence of 4, but failed to incorporate the Ne-aminooxy analogue 2.
The SHKRS/tRNACUA pair, which has been shown to incorporate lysine deriva-
tives containing modifications at the d-position, enabled highly efficient in-
corporation of 2, thereby producing full-length UbBocK6ONH2-His. B) SDS-
PAGE analysis of fractions obtained by Ni-NTA purification of UbBocK6ONH2-
His expressed in the absence or presence of 1 mm 2. C) Deconvoluted ESI-
MS spectrum obtained from LC-MS analysis of purified UbBocK6ONH2-His.
Observed mass: 9488 Da; expected mass: 9490 Da. D) His-tag on UbBocK6-
ONH2-His was removed by treatment with UCH-L3. Observed mass: 8666 Da;
expected mass: 8667 Da. E) The Ne-Boc group on 2 was removed by treat-
ment with 60% aqueous TFA to produce UbK6ONH2. Observed mass:
8566 Da; expected mass: 8567 Da.
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(Figure 3B). We cannot exclude the possibility that a fraction
of the cis isomer was present, and that the trans species selec-
tively crystallised under the conditions tested. However, we
suspect that the steric bulk of the protein reactants ensures
that the favoured regioisomer upon oxime ligation is the trans
species. These findings established that the topology of oxime-
linked conjugates is homogenous and near identical to that of
the native counterpart.
Nonhydrolysable oxime-linked Ub conjugates are potent
DUB inhibitors and bind with affinity comparable to that of
native conjugates
We next determined if the oxime-linked conjugates recapitulat-
ed the biochemical properties of the native isopeptide-linked
conjugates, by measuring their capacity to inhibit DUBs. For
this we determined IC50 values against hydrolysis of the fluoro-
genic substrate Ub-Rhodamine.[30] The conjugates Ub-ox-SUMO
and UbK62-ox inhibited hydrolysis of Ub-Rhodamine by GST-
tagged UCH-L3 (UCH-L3; IC50 : 4.3 (2.5–5.4) and 24.4 (13.8–43.0)
Figure 2. Production of nonhydrolysable oxime conjugates of K6-linked diubiquitin and ubiquitylated SUMO2. A) ESI-MS characterisation of the K6-linked
diUb–oxime conjugate (UbK62-ox). Observed mass: 17094 Da; expected mass: 17097 Da. UbK62-ox was prepared by mixing a twofold excess of Ub-CHO with
UbK6ONH2 under denaturing conditions. The product was purified by RP-HPLC and folded. B) Hydrolytic stability of UbK62-ox. USP21 is highly active against
K6-polyUb. Native K6-linked diUb was readily hydrolysed by USP21, whereas UbK62-ox was completely resistant under the conditions tested. C) SDS-PAGE
analysis of oxime ligation between Ub-CHO and SUMO2K11ONH2. After ligation, the product was purified under native conditions. Reaction catalysed by the
addition of 25 mm aniline. D) SDS-PAGE analysis of the oxime-linked conjugates: UbK62-ox, UbK482-ox and Ub-SUMO-ox. E) ESI-MS characterisation of Ub-
SUMO-ox. Observed mass: 19797 Da; expected: 19801 Da.
Figure 3. Structural characterisation of ubiquitin K6-linked oxime conjugate
by X-ray crystallography. A) The 3.5 æ structure of UbK62-ox (blue) superim-
posed on the crystal structure of native isopeptide-linked K6 diUb (orange):
backbone RMSD 1.1 æ. B) The aminooxylysine amino acid at position 6
(K6ONH2) of the proximal Ub molecule, oxime-linked to the C terminus of
the distal Ub. The mesh corresponds to the 2Fo-Fc electron density map
contoured at 1.0s. This reveals that the oxime linkage is the trans regioiso-
mer.
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nm, respectively; Figure 4A). As both conjugates were potent
inhibitors of UCH-L3 but only Ub-SUMO2K11 is a substrate,
UCH-L3 activity is not dictated by Km, but rather by the signifi-
cantly enhanced catalytic efficiency (kcat) towards Ub-
SUMO2K11. We also tested the inhibitory capacity of UbK482-
ox against the USP family DUB, USP2 (Figure 4B): UbK482-ox
inhibited USP2 with an IC50 of 120.1 (60.1–237.0) nm. In the
inhibitory assays, the DUB concentrations were extremely low
(<2.4 nm) ; therefore, in order to unequivocally confirm that
inhibition was achieved by the oxime-linked conjugates (rather
than trace contamination with Ub-CHO, a known DUB inhibi-
tor),[31] we determined the dissociation constant (Kd) between
USP2 and UbK482-ox by isothermal titration calorimetry (ITC;
Figure 4C). Kd was 98 nm (comparable to IC50), and the binding
stoichiometry was close to unity (0.86), thus confirming that
UbK482-ox was indeed the inhibitory species in the IC50 assay.
In order to demonstrate that the binding affinity of UbK482-ox
recapitulated that of the native conjugate, we characterised
the binding between UbK482 and the catalytically inactive
USP2 mutant, C223A (Figure 4D). The dissociation constants
were comparable (62 and 98 nm). Although the thermodynam-
ic signature was distinct, it is common for minor structural per-
turbations to give rise to significant enthalpy–entropy com-
pensation effects without any gross change in binding
mode.[32]
Immunoblotting of wild-type ubiquitin dimers and oxime
conjugates
Recognition of the oxime conjugates by Ub linkage-specific an-
tibodies against the native counterparts would provide further
validation of the physiological integrity of our conjugates. Fur-
thermore, this would validate using the nonhydrolysable ana-
logues as antigens (thereby capitalising on their enhanced in
vivo half-life) for raising Ub linkage-specific antibodies that
could be used in a reciprocal manner to specifically recognise
the native isopeptide-linked conjugate. Linkage-specific anti-
bodies for K6, K27, K29 and K33 linkages are currently unavaila-
ble but would be powerful tools for elucidating the cellular
roles of these linkage types. The diUb oxime conjugates
(UbK482-ox and UbK62-ox) were analysed by immunoblotting
with linkage-specific antibodies along with Ub dimers with
native isopeptide linkages (UbK62, UbK112, UbK632 and
UbK482 ; Figure 5). The K48 linkage-specific antibody
[33] recog-
nised UbK482-ox, albeit with a slightly weaker signal than for
the native counterpart (Figure 5). Furthermore, as expected,
anti-K63[33] and anti-Met1[34] linkage-specific immunoblotting
did not cross-react with either of the oxime-linked Ub conju-
gates (Figure 5). Additionally, total Ub immunoblotting indicat-
ed that UbK62-ox and UbK482-ox were recognised to the same
degree as their respective native isopeptide conjugates, thus
Figure 4. Oxime-linked ubiquitin conjugates are potent DUB inhibitors and
have comparable affinity to native isopeptide-linked ubiquitin conjugates.
A) UbK62-ox and Ub-SUMO-ox potently inhibit the ubiquitin C-terminal hy-
drolase (UCH) DUB UCH-L3 (meanSD, n=2). Native ubiquitylated SUMO is
a substrate of UCH-L3, whereas UbK62 is not. This suggests that discrimina-
tion of these substrates by UCH-L3 is achieved only by differences in kcat. RF:
relative fluorescence units. B) The ubiquitin-specific protease (USP) DUB
USP2 is inhibited by UbK482-ox. C) ITC demonstrates that Kd is comparable
to IC50. Binding stoichiometry is also close to unity, thus indicating that the
oxime-linked conjugate confers inhibition in the IC50 assays. D) Kd of binding
between native UbK482 and a catalytically inactive USP2 mutant (USP2
C223A) is comparable to that of UbK482-ox binding to wild-type USP2.
Figure 5. Immunoblotting analysis of native isopeptide linked ubiquitin
dimers compared to oxime-linked ubiquitin conjugates. A comparison of
oxime-conjugated ubiquitin dimers (UbK482-ox and UbK62-ox) to wild-type
ubiquitin dimers (UbK62, UbK112, UbK632, UbK482) indicates that oxime-con-
jugated ubiquitin dimers are recognised similarly by an a-Ub (total Ub) anti-
body. Immunoblotting with linkage-selective a-Ub antibodies (a-K48, a-K63
and a-Met1) indicates that UbK482-ox was successfully recognised by the
linkage specific a-K48 antibody. No cross-reactivity with a-K63 or a-Met1
was observed for UbK62-ox or UbK482-ox; only the relevant wild-type Ub
conjugates were recognised. Silver staining was used as a loading control
because of inconsistent immunoreactivity of total Ub antibodies across dif-
ferent linkages types.
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indicating that the oxime linkage did not give rise to aberrant
masking of functional epitopes on the Ub surfaces or to altera-
tion in the topology of the Ub conjugate (Figure 5).
Nonhydrolysable polyUb conjugates by oxime
polymerisation
Ub chains often elicit a biological response only when present
as extended polymers.[35] We hence established a strategy for
the facile preparation of oxime-linked polymeric Ub. We envi-
sioned that the incorporation of 1 site-specifically into Ub
bearing a C-terminal aldehyde moiety would produce a mole-
cule that could undergo self-polymerisation and provide a con-
venient route to extended oxime-linked Ub polymers.[5, 36]
In order to prepare the requisite bifunctional Ub monomer,
we genetically encoded precursor 2 into Ub resides 1–75 ex-
pressed as an intein fusion protein. Thiolysis of the fusion with
sodium mercaptoethanesulfonate (MESNa) generated a truncat-
ed Ub thioester bearing 2 at position 6 (Ub1–75-BocONH2K6-SR),
which was obtained in excellent yield (5 mgL¢1) and purified
by RP-HPLC (Figure S7). Direct aminolysis of Ub1–75-BocONH2K6-
SR with aminoacetaldehyde diethylacetal[23] yielded Ub1–75-
BocONH2K6-acetal with latent bifunctionality (Figure 6A). As a
control, an equivalent species containing 4 was prepared (Ub1–
75-BocK6-acetal ; Figure S8).
Deprotection of the C-terminal diethylacetal and the Boc
protecting groups by incubation in 60% aqueous TFA resulted
in the generation of oligomeric oxime-linked polymers
(polyUb-ox; Figure 6B). Ether precipitation of the polymerised
material was followed by protein folding and its analysis by
SDS-PAGE (Figure 6B). In a control reaction, Ub1–75-BocK6-acetal
did not generate polyUb species, thus indicating that non-spe-
cific imine formation does not occur under these conditions
(Figure 6B). The polymers were resistant to DUB hydrolysis, as
expected (Figure 6C).
These nonhydrolysable Ub polymers would be valuable
tools for affinity purification of linkage-specific DUBs and ubiq-
uitin-binding proteins from cell extracts. Thus, we conjugated
polyUb-ox to biotin, thereby enabling immobilisation on strep-
tavidin resin, by site-specific C-terminal thiazolidine formation
with cysteine-functionalised biotin (Cys-biotin; Figure S9).[37]
Conclusion
We describe a powerful toolkit based on oxime ligation to ad-
vance the study of substrate-specific DUBs and the cellular
roles of polyUb linkages, based on the first genetically directed
incorporation of aminooxy functionality into recombinant pro-
teins. This was achieved by the incorporation of either acid- or
photo-labile protected precursors of aminooxy-l-lysine (1).
Amino acid 1 has extremely high isostery with native lysine as
it differs by conservative substitution of a methylene group by
an oxygen atom at e-position. We demonstrated that 1 could
be site-specifically incorporated into both Ub and SUMO2 via
a protected precursor. This enabled the chemoselective conju-
gation of Ub with Ub-CHO by oxime ligation. The dimeric Ub
conjugates were resistant to DUBs that are highly active
against the native isopeptide-linked counterparts. The oxime
linkage exhibits unprecedented isostery with the native iso-
peptide bond, thus making it a preferred strategy for prepar-
ing nonhydrolysable versions of Ub conjugates. This was dem-
onstrated by structural characterisation of a K6-linked Ub
dimer by X-ray crystallography. The structure of the oxime-
linked species accurately mirrored that of the native counter-
part. Furthermore, unambiguous electron density confirmed
that the trans regioisomer was the predominant, if not exclu-
sive, product upon oxime ligation between proteins. The non-
Figure 6. Upon deprotection, the produced bifunctional Ub molecule, Ub1–75-BocONH2K6-acetal can undergo oxime polymerisation to generate nonhydrolysa-
ble polyubiquitin conjugates. A) LCMS analysis showing successful synthesis of the protected bifunctional Ub monomer, Ub1–75-BocONH2K6-acetal, for generat-
ing oxime-linked polyubiquitin conjugates (observed mass: 8723 Da; expected: 8725 Da). B) SDS-PAGE analysis of the TFA-mediated oxime polymerisation re-
action of Ub-CHO (control) and Ub1–75-ONH2K6-CHO. C) Hydrolytic stability of polyUb-ox against USP21. Native K6-linked diUb was readily hydrolysed by
USP21 whereas polyUb-ox was completely resistant under the conditions tested. *: contaminating species in DUB preparation.
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hydrolysable oxime-linked Ub conjugates also proved to be
nanomolar DUB inhibitors. This high isostery with native conju-
gates, combined with hydrolytic stability, should allow ubiqui-
tin conjugates prepared by this approach to be used as inhibi-
tors of linkage specific processes. Such experiments could be
conducted with cell extracts or in intact cells by microinjection.
As functionalisation of Ub-like (Ubl) proteins[38] with an alde-
hyde group is possible,[23] it should also be possible to prepare
nonhydrolysable variants of Ub-like conjugates (e.g. , NEDD8,
ISG15, SUMO).
Furthermore, we describe the use of oxime chemistry in
polymerisation reactions with bifunctionalised Ubs, in order to
generate polyUb conjugates linked by oxime isopeptide iso-
steres. The expedient synthesis of such conjugates, in conjunc-
tion with their resistance to proteolytic hydrolysis, makes these
new conjugates important probes for studying cellular process-
es that are regulated by polyUb chains.
Finally, we described the incorporation of photocaged ami-
nooxy-l-lysine (3). This should broaden the utility by enabling
conjugation to acid-sensitive recombinant proteins. Although
incorporation efficiency was low, a more efficient PylS/tRNACUA
should be obtainable by directed evolution.[39] Furthermore,
recent reports have demonstrated that the aminooxy group
can undergo rapid biocompatible oxime ligation with di-
aldehyde moieties[40] and in boronic-acid-mediated oxime liga-
tions.[41] These reactions are ultra-fast, rivalling state-of-the-art
inverse electron-demand Diels–Alder bioconjugation between
tetrazines and strained enes.[42] This would enable ultra-fast
photoactivated protein labelling, thereby overcoming the dif-
fusion limit associated with constitutively reactive bioorthogo-
nal handles. Incorporation of the photocaged amino acid into
proteins in live mammalian cells should be achievable, as this
has been shown for structurally similar, photocaged lysine de-
rivatives.[21,43] Furthermore, aldehyde functionality can be ge-
netically encoded by using orthogonal aldehyde tag technolo-
gy (compatible with prokaryotic and mammalian hosts).[44] Ex-
citingly, this could provide a strategy for site-specific photoacti-
vated covalent protein–protein tethering in live cells.
Experimental Section
Production of K6-linked and K48-linked diubiquitin by oxime li-
gation: Using previously reported plasmids, UbBocONH2K6-His and
UbBocONH2K48-His (UbBocONH2KX) were expressed in BL21(DE3)
cells supplemented with 2, followed by His-tag cleavage.[17] Boc-
protecting groups were removed on RP-HPLC-purified material
(2 mg, 233 nmol) by using cold 60% aqueous TFA (400 mL) at 23 8C
for 2 h. Deprotected UbBocONH2KX (UbONH2KX) was then ether
precipitated. Lyophilised Ub-acetal[23] (4.0 mg, 468 nmol) was dis-
solved in denaturing buffer (Na2HPO4 (200 mm, pH 6) with GdnCl
(6m)), then the pH was then adjusted to pH 3 with HCl (1n).
Acetal hydrolysis for 1 h at 37 8C generated Ub-CHO. The pH was
then raised to pH 6 with NaOH (4n) and the solution was then
used to dissolve precipitated Ub-ONH2KX. Oxime ligation (37 8C for
1 h) followed by semi-preparative HPLC (20–50% CH3CN+0.1 %
TFA, over 45 min) afforded UbKX2-ox, which was lyophilised and
refolded by dissolution in Na2HPO4 (200 mm, pH 7.5) with GdnCl
(6m) followed by overnight dialysis against PBS (UbK62-ox: 2.4 mg,
60% yield; UbK482-ox: 3.4 mg, 85% yield).
SUMO–Ub ligation: SUMO-BocONH2K11 was expressed from plas-
mid pCDF-PylT-SUMO2TAG11-His6
[19] and purified by Ni-NTA chro-
matography. Fractions containing SUMO-BocONH2K11 were pooled
and concentrated to ~2 mgmL¢1. An aliquot (600 mL, ~1.2 mg,
106 nmol) was chilled on ice, then TFA (25 mL) was added. The so-
lution was incubated at 37 8C for 4 h, at which time LC-MS analysis
indicated quantitative deprotection. The reaction was neutralised
(pH 7) by addition of NaOH (4n). Ub-CHO (625 mL, 2.9 mgmL¢1,
212 nmol) and aniline (25 mm) was then incubated for 10 min at
37 8C. Deprotected SUMO solution was added to the Ub-CHO/ani-
line solution (SUMO/Ub-CHO, 1:2), incubated at 37 8C for 15 h, with
the reaction monitored by LC-MS. The solution was then concen-
trated to 0.5 mL in 0.5 mL Amicon centrifugal filters (3 KDa MWCO)
and was purified by size-exclusion chromatography with PBS as
running buffer and a Superdex column (S75, 16/60; GE Life Scien-
ces). Subsequent concentration of the appropriate fractions in
15 mL Amicon centrifugal filters (3 KDa MWCO) gave Ub-SUMO-ox
(1 mgmL¢1, 36% yield).
Crystallisation, structure determination and refinement: UbK62-
ox crystallised with cubic morphology at 0.8 mgmL¢1, under previ-
ously reported conditions.[17] The best crystal diffracted to 3.5 æ
(Beamline I02, Diamond Light Source, Harwell, UK). Initial phases
were obtained by molecular replacement by using one ubiquitin
moiety from the K6-diubiquitin structure (PDB ID: 2XK5).[17] Index-
ing and integration was carried out with XDS.[45] Structure refine-
ment was carried out with PHENIX[46] and model building was car-
ried out within COOT.[47] Data collection and refinement statistics
are in Table S1 (PDB ID: 5KHY).
IC50 determination: DUBs, prepared as previously reported,
[26]
were diluted (GST-UCH-L3: 96 pm ; USP2: 2.4 nm) in activation
buffer (Tris·HCl (25 mm, pH 7.5), NaCl (150 mm), DTT (10 mm), BSA
(0.1 mgmL¢1)). A 1:4 dilution series of the oxime-linked conjugates
was then prepared in assay buffer (Tris·HCl (50 mm, pH 7.5), NaCl
(50 mm), DTT (5 mm), BSA (0.1 mgmL¢1)): UbK62-ox: 4.5 mm–
4.4 nm ; Ub- SUMO-ox: 4.5 mm–270 pm ; UbK482-ox, 3.3 mm–814 pm.
DUBs (2.5 mL) were dispensed into a low-volume 384-well plate
(Corning #3676) followed by the dilution series of the oxime-linked
conjugate (2.5 mL). A replicate series was also dispensed. The plate
was incubated at 23 8C for 15 min, then Ub-Rho (2.5 mL, 600 nm in
assay buffer) was added. After 15 min, end point measurements
were taken in a PherastarFS plate reader (BMG Labtech) fitted with
a 480/520 nm fluorescence intensity module. Data were fitted to
a four-parameter dose–response curve in Prism 6 (Graphpad Soft-
ware, La Jolla, CA).
Isothermal titration calorimetry: ITC was conducted on an iTC200
Microcalorimeter (GE Healthcare). All proteins were dialysed against
argon-purged ITC buffer (20 mm HEPES, 100 mm NaCl, 0.25 mm
TCEP, pH 7.5). The sample cell contained either UbK482 WT (9.2 mm)
or UbK482-ox (8.4 mm) ; the concentrations were determined by
using a standard curve of UbK482 (absorbance at 214 nm). The sy-
ringe contained USP2 WT (93 mm) or USP2 C223A (99 mm) ; the con-
centrations were determined by absorbance at 280 nm (for USP2;
e280=41370 Lmol
¢1cm¢1). In all, 13 injections (0.4 mL) were deliv-
ered (0.8 s addition time, interval 120 s). The stirrer speed was set
to 750 rpm, and each binding experiment was carried out at 25 8C.
Water was used in the reference cell, and titrations into buffer
were carried out to assess the enthalpies of dilution. The data was
smoothed with the simple arithmetic function in the Origin 7 data
analysis software (v.7.0552; OriginLab, Northampton, MA).
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Generation of Ub1–75-BocONH2K6-acetal: The previously reported
plasmid pTXB1-Ub1-76[17] underwent two rounds of site-directed
mutagenesis to install a TAG stop codon at Lys6 and to delete the
codon for Gly76, thereby generating pTXB1-Ub1-75TAG6. pTXB1-
Ub1-75TAG6 was transformed into Escherichia coli ER2566 cells
(NEB) to express Ub1–75-BocONH2K6-SR, which was isolated by
chitin-resin affinity purification and on-resin transthioesterification
with (MESNa) over 66 h at 4 8C. After elution, the protein was fur-
ther purified by semi-preparative RP-HPLC, and fractions were
lyophilised (5 mgmL¢1 culture medium). Ub1–75-BocONH2K6-SR was
reconstituted by the addition of DMSO (38 mL) and then MQ water
(155 mL), thus giving a final DMSO concentration of 20% (v/v). Ami-
noacetaldehyde diethyl acetal (97 mL; 4m adjusted to pH 8) was
added to the solution followed by triethylamine (7 mL), thereby
raising the solution to pH 9–10. The solution was vortexed briefly
and incubated at 30 8C. The reaction was monitored by LCMS until
completion. The resulting aminolysis protein product was purified
by RP-HPLC, and appropriate fractions were pooled and lyophilised
(50% yield).
Generation of polyUb-ox: Lyophilised Ub1–75-BocONH2K6-acetal
(2 mg) was reconstituted by the addition of DMSO followed by
PBS (pH 7.4) to a concentration of 2 mgmL¢1 (DMSO, 3% v/v). The
reconstituted solution (250 mL) was chilled, and cold TFA was
added (final, 60%) followed by incubation at 4 8C to RT for 2 h.
Subsequent ice-cold ether precipitation and air-drying afforded
polymerised Ub. The precipitated material was dissolved in
NaH2PO4 (200 mL, 200 mm, pH 8) with GdnCl (6m) then refolded by
overnight dialysis (0.1–0.5 mL dialysis cassette, 3.5 KDa MWCO;
Pierce) against PBS (2 L). SDS-PAGE analysis (4–12% Bis-Tris gel,
MES-SDS, 200 V) was used to assess the extent of polymerisation.
A control reaction was carried out with Ub1–75-BocONH2K6-acetal.
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